Jana NR, Dikshit P, Goswami A, Kotliarova S, Murata S, Tanaka K, et al
As clinicians (even non-prescribing clinicians), I think we need: - Curiosity - An understanding of how it might impact our rehab program design Better evidence, not anecdotes (the studies are mostly animal based) Conversations, not blank stares Because whether we like it or not, this isnt fringe anymore
Note, these products are not pharmaceuticals or medicines and have not been approved by the FDA for the diagnosis, treatment or prevention of any illnesses or disorders
Plus, weve included a handy needle gauge chart for quick reference
MUSE are literally half the size of traditional MSCs, and they have the ability, when administered intravenously, to pass the lungs and make it to the site of inflammation and damage
In addition, the absence of resistance of peptides to breakdown by gastrointestinal proteolytic enzymes (e.g., carboxypeptidases or aminopeptidases) should be mentioned [8], which in practice precludes administrating such a drug to the patient orally and calls for intravenous administration
